Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).
Biogen and Eisai have secured accelerated approval from the US Food and Drug Administration (FDA) for Aduhelm (aducanumab-avwa) as the first and only new treatment for Alzheimer’s disease
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTech’s Covid-19 mRNA vaccine called BNT162b2 to include use
Merck has completed the spinoff of Organon, which has now launched as new women’s health company. Through this transaction, Merck aims to create two patient-focused organisations with improved
Centivax has inked a strategic collaboration with the US Naval Medical Research Center (NMRC) to carry out Phase I trial of Centi-B9, its SARS-CoV-2 antibody. Centi-B9 is intended
German company MorphoSys has signed a definitive agreement to acquire US-based Constellation Pharmaceuticals for approximately $1.7bn. Under the terms of the agreement, MorphoSys’ wholly-owned subsidiary will begin a
Amgen has signed an agreement with Japanese pharmaceutical firm Kyowa Kirin to jointly develop and commercialise Phase III-ready antibody for treating atopic dermatitis. Discovered by Kyowa Kirin, the
South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in
The European Union (EU) has expanded the conditional marketing authorization (CMA) for Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, to include adolescents aged 12 to 15 years. The authorisation
Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m. Under the terms of a definitive agreement signed by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.